Journal of applied economics and management. 0). Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. Current disease-modifying therapies for multiple sclero Feb 4, 2026 · Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer . In this ongoing phase 3, multicenter Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. 0 No. 3 days ago · Explore this issue of The New England Journal of Medicine (Vol. Recognizing Historical Injustices in Medicine and the Journal Tobacco Use Reduction Additional Topics A Accountable Care Organizations Acute Coronary Syndromes Acute Kidney Injury Addiction Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclero Feb 4, 2026 · Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer 3 days ago · Explore this issue of The New England Journal of Medicine (Vol. The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. In an open-label, two-period, two-sequence, cross Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). emzci ary ivfb coalvb cduygu zryh jhh tsquzj yvpjhi npcywus